Navigation Links
CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
Date:3/28/2008

HILTON HEAD ISLAND, S.C., March 28 /PRNewswire/ -- Dr. Roger Kenneth Hershline PhD MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to Bill and Melinda Gates for funding from their Grand Challenges in Global Health initiative. The monies will be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number: 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World Aids Day Conference China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powd
'/>"/>

SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
2. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
3. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
4. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
5. Gates Foundation Seeks Proposals for Innovative Global Health Research
6. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
7. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...lobus Medical, Inc., the largest,privately held sp...nized,leader in motion preservation technology, to...SECURE(R)-C Cervical Artificial Disc IDE study. Th...al motion of the spine in,order to alleviate pain ...n,the treatment of symptomatic cervical disc disea...
(Date:5/8/2008)...wire-FirstCall/ -- Siemens Healthcare and,Laborato... today announced,that they have entered a non-excl... co-develop new clinical diagnostic tests in the a... oncology and diabetes. Under the,agreement, initi...that,could make the biggest impact to patient care...
(Date:5/8/2008)...r Center Investigators to Assess BSI-201 ...-, BRISBANE, Calif., May 8 /- BiPar ...ase 2 clinical trial programs for its lead,product...jor clinical trial,of BSI-201 that BiPar has launc...ials in breast and brain cancer., The company is ...
(Date:5/7/2008)...erred Induction Dosing Regimen, SEATTLE, May 7 /P...c.,(Nasdaq: TRBN ) today announced that its partn...SE: WYE ), has commenced patient dosing in the ne...with rheumatoid arthritis,(RA). In collaboration w...RU-015, SBI-087 and other CD20-directed products.,...
Breaking Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4Chemistry turns killer gas into potential cure 805 1Chemistry turns killer gas into potential cure 805 2Neuromed Concludes a Special Protocol Assessment 28SPA 29 with FDA for a Pivotal Phase 3 Study on NMED 1077 3669 1Neuromed Concludes a Special Protocol Assessment 28SPA 29 with FDA for a Pivotal Phase 3 Study on NMED 1077 3669 2Neuromed Concludes a Special Protocol Assessment 28SPA 29 with FDA for a Pivotal Phase 3 Study on NMED 1077 3669 3FDA Expands VELCADE 28R 29 28Bortezomib 29 for Injection Label for Patients with Multiple Myeloma 3665 1FDA Expands VELCADE 28R 29 28Bortezomib 29 for Injection Label for Patients with Multiple Myeloma 3665 2FDA Expands VELCADE 28R 29 28Bortezomib 29 for Injection Label for Patients with Multiple Myeloma 3665 3FDA Expands VELCADE 28R 29 28Bortezomib 29 for Injection Label for Patients with Multiple Myeloma 3665 4FDA Expands VELCADE 28R 29 28Bortezomib 29 for Injection Label for Patients with Multiple Myeloma 3665 5FDA Expands VELCADE 28R 29 28Bortezomib 29 for Injection Label for Patients with Multiple Myeloma 3665 6Labopharm appeals FDAs decision on once daily tramadol 3661 1Labopharm appeals FDAs decision on once daily tramadol 3661 2
...SOUTH SAN FRANCISCO, Calif., April 13, 2007,/PRNew...today,announced that the company will present data... for Cancer Research (AACR) being held,April 14-18...esented in a poster session will focus on,non-clin...t,inhibitor of cyclin-dependent kinases (CDKs) 2, ...
...ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007,/PR...est initial,registration clinical trial program ev...ficacy and safety information on the,investigation...,renal anemia associated with chronic kidney disea...is. Three data analyses were,presented at the Nati...
Other Medicine Technology:Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research 2Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 2Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 3Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease 4
(Date:5/9/2008)...f 30% of infected patients in U.K., researchers sa...ritish research into Steno, one the most recent "s...um has an incredible ability to resist antibiotics...d findings. , Steno, short for Stenotrophomon...ch as around taps and shower heads, and can be tra...
(Date:5/9/2008)...ble or Improve in 86% at Six Months, TORONTO, May...s Inc.,(TSX: NDQ), a developer of real-time imagin...ing room, today announced that independent data wa... in Vision and,Ophthalmology (ARVO) conference in ...Data from two of the three European hospitals curr...
(Date:5/9/2008)...profit remains stable; net loss per ...e in Canadian dollars unless otherwise noted), BE...che Life Sciences,Inc. (TSX: BNC), a research-base...mpany, today announced financial results for the t... 31, 2008., "One highlight of our third quarter w...
(Date:5/9/2008)...w Technologies in Surface and Volume ...9 /PRNewswire-FirstCall/ -- ANSYS, Inc. (Nasdaq:,A...d technologies designed,to optimize product develo...rsion 5.0 of its TGrid(TM) advanced mesh generatio...processor for fluid flow analysis. It is,used to c...
Breaking Medicine News(10 mins):Health News:Steno 'Superbug' Genome Shows Extreme Drug Resistance 2Health News:Novadaq's OPTTX System Data Presented at ARVO 2Health News:Novadaq's OPTTX System Data Presented at ARVO 3Health News:Novadaq's OPTTX System Data Presented at ARVO 4Health News:Bioniche Reports Fiscal 2008 Third Quarter 2Health News:Bioniche Reports Fiscal 2008 Third Quarter 3Health News:Bioniche Reports Fiscal 2008 Third Quarter 4Health News:Bioniche Reports Fiscal 2008 Third Quarter 5Health News:Bioniche Reports Fiscal 2008 Third Quarter 6Health News:Bioniche Reports Fiscal 2008 Third Quarter 7Health News:Bioniche Reports Fiscal 2008 Third Quarter 8Health News:Bioniche Reports Fiscal 2008 Third Quarter 9Health News:Bioniche Reports Fiscal 2008 Third Quarter 10Health News:Bioniche Reports Fiscal 2008 Third Quarter 11Health News:Bioniche Reports Fiscal 2008 Third Quarter 12Health News:Bioniche Reports Fiscal 2008 Third Quarter 13Health News:Bioniche Reports Fiscal 2008 Third Quarter 14Health News:Bioniche Reports Fiscal 2008 Third Quarter 15Health News:TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity 2Health News:TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity 3
...and that rocks the cradle rules the world! Rightly... child from the moment of birth. //Enabling the ch...not be mere wishful-thinking, and in this age of i...clearly understood, as a foundation for all round ...
... blood test developed by Dr. Edward A. Hirschowitz... early stages in people who are at high risk for d...ing cause of cancer death in United States and aro... diagnosed at a later stage. The incidence of lun...
...rches have found that different genes may be invol...e also noted that other genes may also be involved...pmental disorder in a new study published in the o... Genetics. The study also provides new evidence f...
...orld's first and only cervical cancer vaccine, Gar...s that causes most cervical cancers, may go on sal...he vaccine developed by US pharmaceutical company ...nt effective against the two main strains of the H...
Other Medicine News:Health News:Breast Milk: The Mother of All Milk for Infants 2Health News:Breast Milk: The Mother of All Milk for Infants 3Health News:New Blood Test For Early Detection Of Lung Cancer 2Health News:New Findings on Autism Research 2
Replacment Tubing
J Cortex Extrator - Angled Left
J Cannula
Bimanual Aspiration Cannula
Medicine Products: